Analysts Bullish Ahead of Colorectal Cancer Readout for CytomX Therapeutics, Inc. (CTMX)

TheFly reported connected January 20 that Piper Sandler raised its terms people connected CTMX to $10 from $6.50, keeping an Overweight rating. The steadfast noted that Initial Phase 1 information for varsetatug maseatecan in heavy pretreated metastatic colorectal crab showed a 28% wide effect rate, 94% illness power rate, and 5.8-month median PFS. This quarter, updated information with imaginable dose-dependent benefits from astir 100 patients crossed 3 attraction cohorts are anticipated.

Similarly, connected the aforesaid day, Barclays expert Etzer Darout besides raised the terms people connected CytomX Therapeutics, Inc. (NASDAQ:CTMX) to $8 from $6 and maintained an Overweight rating. The imminent readout connected colorectal crab was mentioned by the steadfast arsenic providing an charismatic risk-reward profile.

CytomX Therapeutics, Inc. (NASDAQ:CTMX) is simply a clinical‑stage biopharmaceutical institution that develops Probody therapeutics, condition‑activated antibody prodrugs designed to amended crab targeting and trim off‑tumor toxicity. Its pipeline includes innovative immuno‑oncology and targeted therapies aimed astatine enhancing information and efficacy for coagulated tumors and different superior diseases.

While we admit the imaginable of CTMX arsenic an investment, we judge definite AI stocks connection greater upside imaginable and transportation little downside risk. If you're looking for an highly undervalued AI banal that besides stands to payment importantly from Trump-era tariffs and the onshoring trend, spot our escaped study connected the best short-term AI stock.

READ NEXT: 12 Best Multibagger Stocks to Buy Heading into 2026 and 7 Best Rising Tech Stocks to Buy Now.

Disclosure: None.